Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,947 public trials 2,015 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, Not Recruiting

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

NCT05451810

Conditions
Classic Follicular Lymphoma, Diffuse Large B-cell Lymphoma, Disease Attributes, +14 more
Locations
  • Infirmary Health - Infirmary Cancer Care at Mobile Infirmary /ID# 264630 Mobile, Alabama, United States
  • University of Arkansas for Medical Sciences /ID# 244562 Little Rock, Arkansas, United States
  • Highlands Oncology Group, PA /ID# 245002 Springdale, Arkansas, United States
  • Beverly Hills Cancer Center /ID# 255327 Beverly Hills, California, United States
View all 72 locations
View Trial Details
Active, Not Recruiting

Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL

NCT04722848

Conditions
ALL, Adult, Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive), Hematologic Diseases, +11 more
Locations
  • Area Vasta N. 5 Ascoli Piceno - S. Benedetto Del Tronto, Presidio Ospedaliero Av5 Osp. Gen. Prov.Le "C.G.Mazzoni" - Uoc Ematologia Ascoli Piceno, Italy
  • Irccs Oncologico Istituto Tumori Giovanni Paolo Ii - Bari - Uo Ematologia Bari, Italy
  • Asst Papa Giovanni Xxiii - Ospedale Di Bergamo - Sc Ematologia Bergamo, Italy
  • As Dell'Alto Adige, Ospedale Centrale Di Bolzano - Ematologia E Centro Trapianto Midollo Osseo Bolzano, Italy
View all 15 locations
View Trial Details
Active, Not Recruiting

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

NCT05578976

Conditions
Diffuse Large B-cell Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +13 more
Locations
  • University of Arizona Cancer Center - North Campus /ID# 227463 Tucson, Arizona, United States
  • Yuma Regional Medical Center /ID# 261527 Yuma, Arizona, United States
  • University of Arkansas for Medical Sciences /ID# 225703 Little Rock, Arkansas, United States
  • CBCC Global Research, Inc. /ID# 262037 Bakersfield, California, United States
View all 331 locations
View Trial Details
Active, Not Recruiting

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

NCT04782687

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +18 more
Locations
  • Arizona Oncology Associates, PC - HOPE Tucson, Arizona, United States
  • Rocky Mountain Cancer Centers Denver, Colorado, United States
  • Maryland Oncology Hematology, P.A. Columbia, Maryland, United States
  • New York Oncology Hematology, P.C. Albany, New York, United States
View Trial Details
Active, Not Recruiting

A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant

NCT04096066

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • AO "SS. Antonio e Biagio" Alessandria, Italy
  • AOU Ospedali Riuniti Umberto I Ancona, Italy
  • Ospedale Mazzoni Ascoli Piceno, Italy
  • Policlinico di Bari Bari, Italy
View all 40 locations
View Trial Details
Active, Not Recruiting

Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma

NCT05263583

Conditions
Burkitt Lymphoma, C-MYC/BCL2 Double-Hit High-Grade B-Cell Lymphoma, C-MYC/BCL6 Double-Hit High-Grade B-Cell Lymphoma, +24 more
Locations
  • Beijing Cancer Hospital Beijing, China
  • Sun Yat-sen University Cancer Center Guangzhou, China
  • Henan Cancer Hospital Henan, China
  • Shanghai East Hospital Pudong, China
View Trial Details
Active, Not Recruiting

A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)

NCT05885464

Conditions
Hematologic Diseases, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Stanford University School of Medicine Stanford, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • University of Chicago Chicago, Illinois, United States
  • The University of Kansas Cancer Center Fairway, Kansas, United States
View Trial Details
Active, Not Recruiting

A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM

NCT04786028

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • Nova Scotia Health - QEII Health Sciences Centre Halifax, Nova Scotia, Canada
  • Hamilton Health Sciences Centre Hamilton, Ontario, Canada
  • The Ottawa Hospital General Campus Ottawa, Ontario, Canada
View Trial Details

Related conditions